LAC MED BERHAD **202401049485 (1595329H)**
G-03A-3, Plaza Kelana Jaya, Jalan SS7/13A, 47301 Petaling Jaya,
Selangor, Malaysia.
Tel: 03-7652 1088
Ref. No.: LACMED/SC/2505-01

PRESS RELEASE

LAC Med financials poised to accelerate in 2H26

- ***2Q26 net profit up five times QoQ to RM5.3 million, on 55.1% higher revenue of RM45.6 million***
- ***Order book stands at RM246.9 million as at 31 July 2026, providing earnings visibility for next three to four years***
  RM769.8 million tender book as at 31 July 2026 underscores strong deal pipeline momentum, driven by active public healthcare bids

Selangor, Malaysia, 19 August 2026 – MedTech solutions provider, LAC Med Berhad (LAC Med or the Group; `Bloomberg: LACMED MK`) is all set to convert its robust order book into sales and profits in the second half of 2026, driven by the healthcare sector's typical procurement cycle of back-half weighted.



In the second quarter ended 30 June 2026 (2Q26), the Group's financial performance accelerated with revenue rising 55.1% to RM45.6 million, compared to RM29.4 million in the preceding quarter (1Q26). Similarly, net profit in 2Q26 leaped five times to RM5.3 million, from RM1.0 million in 1Q26.

Driving overall growth in 2Q26, all of the LAC Med's business segments delivered solid quarter-on-quarter revenue expansion—*Supply and Integration of Medical Devices* grew 102.8% to RM21.7 million, *Supply of Medical Equipment* rose 31.3% to RM15.1 million, and *Supply of Related Products & Services* increased 22.2% to RM8.8 million.

Fuelling the Group's earnings ahead, its order book stood at RM246.9 million as at 31 July 2026, providing earnings visibility for the next three to four years.

"Throughout the first half of 2026, we actively expanded the market presence of our 11 brands—particularly the nine added since 2023, leveraging our two-decade track record to accelerate product adoption. As a result, we made headway not only in market penetration but also in financial performance.

We see further upside ahead in 2H26 as we prepare for more bidding opportunities and recognition of order book execution, tapping into the rising procurement activity across healthcare service providers. With an extensive portfolio of over 1,200 active SKUs, we are ready to meet this demand and drive revenue growth, outperforming our first half financials.

To bolster earnings visibility and improve profit margins, we remain focused on scaling our recurring revenue streams across healthcare IT, consumables, and repair and maintenance services. In parallel, we are sharpening our capabilities to secure more higher-value projects."

Mr. Liew Yoon Poh ("刘任堡")
Group Chief Executive Officer of LAC Med Berhad

LAC Med's tender book grew from RM690.9 million as at 30 April 2026 to RM769.8 million as at 31 July 2026, highlighting strong deal pipeline momentum as the Group actively pursue public healthcare project bids.

Meanwhile, LAC Med is striving for 20% of its total revenue to derive from recurring sources—driven by healthcare IT solutions, consumables, and repair & maintenance services—to enhance earnings visibility and strengthen profit margins.

Mr. Liew added: “The RM105.7 million in new contracts secured to date—for the supply and delivery of reagents with related items—through our newly onboarded principal highlights our clear traction in driving high-visibility recurring revenue. Beyond financials, this achievement reinforces LAC Med’s standing as a trusted partner and key enabler in advancing Malaysia's healthcare sector.”

In the first half ended 30 June 2026 (1H26), revenue and net profit recorded RM75.0 million and RM6.3 million, repectively. By comparison, the revenue and net profit were higher at RM95.0 million and RM10.1 million, respectively, in the previous corresponding period (1H25).

The better performance in 1H25 compared to 1H26 was also due to a one-off revenue adjustment of approximately RM6 million from the Supply and Integration of Medical Devices segment that was deferred from FY2024.

There is no comparison for 2Q26 to the preceding year’s corresponding quarter ended 30 June 2025 as LAC Med was listed on the Main Market of Bursa Malaysia Securities Berhad on 10 December 2025.

LAC MED BERHAD 202401049485 (1595329H)
G-03A-3, Plaza Kelana Jaya, Jalan SS7/13A, 47301 Petaling Jaya,
Selangor, Malaysia.
Tel: 03-7652 1088
Ref. No.: LACMED/SC/2505-01

About LAC Med Berhad (LAC Med; the Group)

Established in 2004, LAC Med is a leading integrated medical devices and solutions provider. Through its subsidiaries, LAC Med has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,600 units of medical equipment and supports over 300 active clients across Malaysia's healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med's competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia and Indonesia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, Harrison.ai (formerly known as annalise.ai), Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media and investor relations enquiries, please contact:

Mr. Terence Loo	terence@aquilas.com.my	T:03-2711 1391/ M: 012-629 5618
Mr. Tee Wei Keat	weikeat@aquilas.com.my	T:03-2711 1391/ M: 012-309 5448